On the Way to Another Revolution: Weight-Loss Injections May Reduce Breast Cancer Recurrence

A new observational study suggests that GLP-1 weight-loss drugs may reduce the risk of breast cancer recurrence. Experts emphasize that this is only a statistical association, not proof of causation. The effect is attributed to metabolic changes: weight loss reduces fat tissue, which produces estrogen that promotes tumors, and lowers chronic inflammation. Randomized controlled trials are needed for confirmation.

A new observational study suggests that drugs from the GLP-1 family, used to treat obesity and diabetes, may reduce the risk of breast cancer recurrence. Experts emphasize that these are only observational findings, which identified a statistical association between the treatment and outcomes, but do not prove causation. The main hypothesis is that the effect stems from metabolic changes: weight loss reduces fat tissue, which produces estrogen that promotes the growth of breast tumors, and lowers chronic inflammation. However, randomized controlled trials are required to prove a causal link, and none have been published on the subject yet. Experts clarify that these drugs are not a substitute for standard breast cancer treatments, such as surgery, radiation, chemotherapy, or hormonal therapy, and women receiving them should continue oncological follow-up.